Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


06.03.2017

3 BMC Cancer
2 BMC Urol
1 Cancer
3 Cancer Res
1 Eur Radiol
6 Eur Urol
2 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
2 J Urol
1 N Engl J Med
2 Nat Rev Urol
3 PLoS One
1 Prog Urol
4 Prostate
2 Urol Int
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. LUNDON DJ, Boland A, Prencipe M, Hurley G, et al
    The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
    BMC Cancer. 2017;17:163.
    PubMed     Text format     Abstract available

  2. KUMAR SR, Bryan JN, Esebua M, Amos-Landgraf J, et al
    Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.
    BMC Cancer. 2017;17:158.
    PubMed     Text format     Abstract available

  3. CHEVRIER M, Bobbala D, Villalobos-Hernandez A, Khan MG, et al
    Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.
    BMC Cancer. 2017;17:157.
    PubMed     Text format     Abstract available


    BMC Urol

  4. HUANG H, Wang W, Lin T, Zhang Q, et al
    Comparison of the complications of traditional 12 cores transrectal prostate biopsy with image fusion guided transperineal prostate biopsy.
    BMC Urol. 2016;16:68.
    PubMed     Text format     Abstract available

  5. ANGENETE E, Angeras U, Borjesson M, Ekelund J, et al
    Physical activity before radical prostatectomy reduces sick leave after surgery - results from a prospective, non-randomized controlled clinical trial (LAPPRO).
    BMC Urol. 2016;16:50.
    PubMed     Text format     Abstract available


    Cancer

  6. VERMA V, Mishra MV, Mehta MP
    A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
    Cancer. 2016;122:1483-501.
    PubMed     Text format     Abstract available


    Cancer Res

  7. YU X, Wang H, Li X, Guo C, et al
    Activation of the MDA-5-IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity.
    Cancer Res. 2016;76:2166-76.
    PubMed     Text format     Abstract available

  8. PASERO C, Gravis G, Guerin M, Granjeaud S, et al
    Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.
    Cancer Res. 2016;76:2153-65.
    PubMed     Text format     Abstract available

  9. THOMAS JD, Longen CG, Oyer HM, Chen N, et al
    Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer.
    Cancer Res. 2017 Feb 24. pii: canres.1055.2016.
    PubMed     Text format     Abstract available


    Eur Radiol

  10. PARK SY, Oh YT, Jung DC, Cho NH, et al
    Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.
    Eur Radiol. 2016;26:2502-9.
    PubMed     Text format     Abstract available


    Eur Urol

  11. SPRATT DE, Lee JY, Dess RT, Narayana V, et al
    Vessel-sparing Radiotherapy for Localized Prostate Cancer to Preserve Erectile Function: A Single-arm Phase 2 Trial.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30096.
    PubMed     Text format     Abstract available

  12. JONES TA, Marks LS
    Re: A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30101.
    PubMed     Text format    

  13. MATEO J, Sharp A, de Bono JS
    Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30094.
    PubMed     Text format    

  14. MOURACADE P
    Re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2
    Eur Urol. 2017 Feb 18. pii: S0302-2838(17)30085.
    PubMed     Text format    

  15. TAAFFE DR, Newton RU, Spry N, Joseph D, et al
    Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.
    Eur Urol. 2017 Feb 26. pii: S0302-2838(17)30108.
    PubMed     Text format     Abstract available

  16. KAPOOR J, Lamb AD, Murphy DG
    Re: Diagnostic Accuracy of Multi-parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    Eur Urol. 2017 Feb 23. pii: S0302-2838(17)30103.
    PubMed     Text format    


    Int J Radiat Oncol Biol Phys

  17. SHAIKH T, Li T, Handorf EA, Johnson ME, et al
    Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017;97:722-731.
    PubMed     Text format     Abstract available

  18. BEKELMAN JE, Lee WR
    Six Questions to Ask Before We Shorten Radiation Treatments for Intact Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017;97:718-721.
    PubMed     Text format    


    J Clin Oncol

  19. D'AMICO AV
    Active Surveillance Versus Treatment of Prostate Cancer: Should Metastasis Be the Primary End Point?
    J Clin Oncol. 2017 Feb 27:JCO2016709527. doi: 10.1200/JCO.2016.70.9527.
    PubMed     Text format    


    J Urol

  20. BOESEN L, Norgaard N, Logager V, Thomsen HS, et al
    Clinical outcome following a low-suspicion multiparametric prostate MRI or benign MRI-guided biopsy to detect prostate cancer: A follow-up study in men with prior negative transrectal ultrasound-guided biopsies.
    J Urol. 2017 Feb 21. pii: S0022-5347(17)30297-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available

  21. HIGANO CS
    The Role of Intermittent Androgen Deprivation Therapy for Prostate Cancer.
    J Urol. 2017 Feb 20. pii: S0022-5347(17)30286-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


    N Engl J Med


  22. Case 39-2016: A Man with a History of Prostate Cancer and Recent Rectal Bleeding.
    N Engl J Med. 2017;376:897-8.
    PubMed     Text format    


    Nat Rev Urol

  23. STONE L
    Prostate cancer: Fatal interaction: a new target identified.
    Nat Rev Urol. 2017 Feb 21. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  24. SIDAWAY P
    Prostate cancer: Targeting lipid metabolism.
    Nat Rev Urol. 2017 Feb 21. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    PLoS One

  25. BLUTE ML JR, Damaschke N, Wagner J, Yang B, et al
    Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.
    PLoS One. 2017;12:e0172048.
    PubMed     Text format     Abstract available

  26. LI CC, Hou YC, Yeh CL, Yeh SL, et al
    Retraction: Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Prostate Cancer Cell Migration and Invasion Induced by Tumor-Associated Macrophages.
    PLoS One. 2017;12:e0173325.
    PubMed     Text format    

  27. CHUNG SD, Kao LT, Lin HC, Xirasagar S, et al
    Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.
    PLoS One. 2017;12:e0173266.
    PubMed     Text format     Abstract available


    Prog Urol

  28. CHAHWAN C, Doerfler A, Brichart N, Bouye S, et al
    Prostate cancer before renal transplantation: A multicentre study.
    Prog Urol. 2017 Feb 22. pii: S1166-7087(17)30015.
    PubMed     Text format     Abstract available


    Prostate

  29. SZULKIN R, Clements MS, Magnusson PK, Wiklund FE, et al
    Estimating Heritability of Prostate Cancer-Specific Survival Using Population-Based Registers.
    Prostate. 2017 Mar 1. doi: 10.1002/pros.23344.
    PubMed     Text format     Abstract available

  30. PILLING AB, Hwang O, Boudreault A, Laurent A, et al
    IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-alpha Signaling.
    Prostate. 2017 Feb 27. doi: 10.1002/pros.23327.
    PubMed     Text format     Abstract available

  31. ZHANG Q, Liu S, Ge D, Cunningham DM, et al
    Targeting Th17-IL-17 pathway in prevention of micro-invasive prostate cancer in a mouse model.
    Prostate. 2017 Feb 27. doi: 10.1002/pros.23343.
    PubMed     Text format     Abstract available

  32. SAETER T, Vlatkovic L, Waaler G, Servoll E, et al
    Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study.
    Prostate. 2017 Feb 27. doi: 10.1002/pros.23326.
    PubMed     Text format     Abstract available


    Urol Int

  33. PORCARO AB, De Luyk N, Corsi P, Sebben M, et al
    Association between Basal Total Testosterone Levels and Tumor Upgrading in Low and Intermediate Risk Prostate Cancer.
    Urol Int. 2017 Mar 1. doi: 10.1159/000459632.
    PubMed     Text format     Abstract available

  34. PORCARO AB, de Luyk N, Corsi P, Sebben M, et al
    Clinical Factors Predicting and Stratifying the Risk of Lymph Node Invasion in Localized Prostate Cancer.
    Urol Int. 2017 Mar 1. doi: 10.1159/000458763.
    PubMed     Text format     Abstract available


    Urology

  35. AUFFENBERG GB, Merdan S, Miller DC, Singh K, et al
    Evaluation of Prostate Cancer Risk Calculators for Shared-Decision Making Across Diverse Urology Practices in Michigan.
    Urology. 2017 Feb 22. pii: S0090-4295(17)30165.
    PubMed     Text format     Abstract available

  36. GORDETSKY J, Rais-Bahrami S, Epstein JI
    Pathological Findings in Multiparametric MRI/Ultrasound Fusion Guided Biopsy: Relation to Prostate Cancer Focal Therapy.
    Urology. 2017 Feb 23. pii: S0090-4295(17)30163.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: